Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Warfarin monitoring economic evaluation of point of care self-monitoring compared to clinic settings.

Craig JA, Chaplin S, Jenks M.

J Med Econ. 2014 Mar;17(3):184-90. doi: 10.3111/13696998.2013.877468. Epub 2014 Jan 24.

PMID:
24351064
2.

Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling.

Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F.

Health Technol Assess. 2007 Oct;11(38):iii-iv, ix-66. Review.

3.
4.

Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.

Carles M, Brosa M, Souto JC, Garcia-Alamino JM, Guyatt G, Alonso-Coello P.

BMC Health Serv Res. 2015 Jul 28;15:289. doi: 10.1186/s12913-015-0934-9.

5.
6.

Economic evaluation of a randomized controlled trial of pharmacist-supervized patient self-testing of warfarin therapy.

Gallagher J, Mc Carthy S, Woods N, Ryan F, O' Shea S, Byrne S.

J Clin Pharm Ther. 2015 Feb;40(1):14-9. doi: 10.1111/jcpt.12215. Epub 2014 Oct 8.

PMID:
25295834
7.

The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring.

Gaw JR, Crowley S, Monagle P, Jones S, Newall F.

Thromb Res. 2013 Jul;132(1):26-31. doi: 10.1016/j.thromres.2013.04.028. Epub 2013 Jun 6.

PMID:
23746471
8.

Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.

Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.

Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Review.

9.

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy.

Lafata JE, Martin SA, Kaatz S, Ward RE.

J Gen Intern Med. 2000 Jan;15(1):31-7.

10.
11.

Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.

Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, Asukai Y, Saka Ö, Evers T, Faes P, Vansieleghem S, De Ruyck M.

Pharmacoeconomics. 2013 Oct;31(10):909-18. doi: 10.1007/s40273-013-0087-9.

12.

Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.

Mensch A, Stock S, Stollenwerk B, Müller D.

Pharmacoeconomics. 2015 Mar;33(3):271-83. doi: 10.1007/s40273-014-0236-9.

PMID:
25404426
13.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

14.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

15.

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.

Patrick AR, Avorn J, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):429-36. doi: 10.1161/CIRCOUTCOMES.108.808592. Epub 2009 Jul 21.

16.

Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.

Ademi Z, Pasupathi K, Liew D.

Eur J Prev Cardiol. 2015 Mar;22(3):344-53. doi: 10.1177/2047487313514019. Epub 2013 Nov 26.

PMID:
24281250
17.

Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.

Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA.

CMAJ. 2006 Jun 20;174(13):1847-52.

18.

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.

Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, Hurley JS, Pezzella S, Kaatz S.

Ann Pharmacother. 2005 Mar;39(3):446-51. Epub 2005 Feb 8.

PMID:
15701783
19.

Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand.

Jarungsuccess S, Taerakun S.

Clin Ther. 2014 Oct 1;36(10):1389-94.e4. doi: 10.1016/j.clinthera.2014.08.016. Epub 2014 Sep 27.

PMID:
25267360
20.

Supplemental Content

Support Center